PharmaCyte Biotech Approves 1-for-19 Reverse Stock Split to Meet Nasdaq Compliance
PharmaCyte Biotech (PMCB) has announced that its shareholders have approved a 1-for-19 reverse stock split. The action is scheduled to take effect on November 12, 2026. This move will consolidate the company's outstanding common stock from approximately 10.75 million shares down to roughly 566,087 shares. The primary objective of this corporate action is to boost the per-share trading price. By increasing the share value through consolidation, PharmaCyte Biotech aims to regain compliance with Nasdaq's minimum bid price requirements, which are necessary to maintain its listing on the exchange.
Tickers: $PMCB
Topics: Nasdaq compliance reverse stock split share consolidation
Read the full article at Seeking Alpha
Part of the story PharmaCyte Biotech Approves 1-for-19 Reverse Stock Split to Meet Nasdaq Compliance (3 articles)